A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 4,799 shares of NBIX stock, worth $610,288. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,799
Holding current value
$610,288
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$114.58 - $153.15 $549,869 - $734,966
4,799 New
4,799 $553 Million
Q3 2021

Nov 01, 2021

SELL
$86.18 - $99.03 $378,588 - $435,038
-4,393 Closed
0 $0
Q2 2021

Aug 30, 2021

BUY
$89.43 - $102.27 $115,096 - $131,621
1,287 Added 41.44%
4,393 $428,000
Q1 2021

May 20, 2021

BUY
$87.57 - $119.4 $60,510 - $82,505
691 Added 28.61%
3,106 $302,000
Q4 2020

Mar 08, 2021

BUY
$86.91 - $108.33 $209,887 - $261,616
2,415 New
2,415 $231,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Holding Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Holding Ag with notifications on news.